Image may differ
AESKULISA®
Reference:
6033
Designation:
Cytomegalovirus IgM
Intended use:

The AESKULISA® Cytomegalovirus IgG and IgM tests are qualitative and quantitative immunoassays for the detection of human IgG and IgM antibodies in serum or plasma directed against Cytomegalovirus. The AESKULISA® Cytomegalovirus IgM serves as an initial test for the detection of acute infections. The AESKULISA® Cytomegalovirus IgG allows the confirmation of pathogen contact and supports the determination of the immune status. The AESKULISA® Cytomegalovirus gB IgG is a qualitative and quantitative immunoassay for the detection of human IgG antibodies in serum or plasma against HCMV glycoprotein B (gB). The interpretation of the results can only be made in connection with the clinical picture. A diagnosis should not be based solely on the results of the test performed, but should always be made taking into account all clinical and laboratory findings. Further tests should be carried out for confirmation. AESKULISA® immunoassays are suitable for use by healthcare professionals with appropriate professional training in the use of in vitro diagnostics.

Method:
ELISA
Conjugate:
IgM
Analysis:
Qualitative
,
Quantitative
Cut Off:
Cut-off control
Measurement range:
Kit-specific
QC certificate
Provisions:
1 x 96
Kit-Configuration:
Single
Number of antigens:
1
Registration:
CE marking
Coated Antigens:
Purified and inactivated cytomegalovirus
strain AD-169
AESKULISA®

6033

Cytomegalovirus IgM

Image may differ
Intended use:

The AESKULISA® Cytomegalovirus IgG and IgM tests are qualitative and quantitative immunoassays for the detection of human IgG and IgM antibodies in serum or plasma directed against Cytomegalovirus. The AESKULISA® Cytomegalovirus IgM serves as an initial test for the detection of acute infections. The AESKULISA® Cytomegalovirus IgG allows the confirmation of pathogen contact and supports the determination of the immune status. The AESKULISA® Cytomegalovirus gB IgG is a qualitative and quantitative immunoassay for the detection of human IgG antibodies in serum or plasma against HCMV glycoprotein B (gB). The interpretation of the results can only be made in connection with the clinical picture. A diagnosis should not be based solely on the results of the test performed, but should always be made taking into account all clinical and laboratory findings. Further tests should be carried out for confirmation. AESKULISA® immunoassays are suitable for use by healthcare professionals with appropriate professional training in the use of in vitro diagnostics.

Method:
ELISA
Conjugate:
IgM
Analysis:
Qualitative
,
Quantitative
Cut Off:
Cut-off control
Measurement range:
Kit-specific
QC certificate
Provisions:
1 x 96
Kit-Configuration:
Single
Number of antigens:
1
Registration:
CE marking
Coated Antigens:
Purified and inactivated cytomegalovirus
strain AD-169
Downloads
All related documents and information clearly summarized

Instructions for Use

Safety Data Sheet